Urothelial Cancer
Symptoms, Doctors, Treatments, Advances & More

Urothelial Cancer Overview

Save information for later
Sign Up

Learn About Urothelial Cancer

What is the definition of Urothelial Cancer?
Urothelial cancer, also known as transitional cell carcinoma, affects the kidney (renal) pelvis or ureter (tube) that drains urine from the kidney to the bladder and/or the lining of the inside of the bladder. It is the most common form of bladder cancer and occurs more frequently in men and older adults. The cause of urothelial cancer is unknown; however, some suspected causes are chronic irritation of the kidney from pain medicines, exposure to manufacturing chemicals and dyes, smoking or other tobacco use, past radiation exposure, and parasitic infections.
What are the symptoms of Urothelial Cancer?
Symptoms of urothelial cancer include fatigue, unexplained weight loss, loss of appetite, anemia, constant back pain, flank pain, pelvic pain, urinary urgency, pain, burning, or discomfort when urinating, or blood in urine (hematuria).
Not sure about your diagnosis?
Check Your Symptoms
What are the current treatments for Urothelial Cancer?
Treatment for urothelial cancer includes surgery and chemotherapy. Bladder cancer can recur after treatment; therefore, long-term follow-up is necessary.
Who are the top Urothelial Cancer Local Doctors?
Elite in Urothelial Cancer
Elite in Urothelial Cancer
Referral may be required

Prostate Cancer Center

1825 Fourth St., Sixth Floor, 
San Francisco, CA 
415-353-7171
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Sima Porten is an Oncologist practicing medicine in San Francisco, California. Dr. Porten is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. She is also highly rated in 11 other conditions, according to our data. Her clinical expertise encompasses Bladder Cancer, Urothelial Cancer, Muscle Invasive Bladder Cancer, Nephrectomy, and Reconstructive Urology Surgery. Dr. Porten is board certified in American Board Of Urology, Urology. Dr. Porten is currently accepting new patients.

Elite in Urothelial Cancer
Elite in Urothelial Cancer
Referral may be required

City Of Hope Comprehensive Cancer Center-Duarte

1500 Duarte Rd, 
Duarte, CA 
888-304-3959
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Sumanta Pal is an Oncologist practicing medicine in Duarte, California. Dr. Pal is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. He is also highly rated in 25 other conditions, according to our data. His clinical expertise encompasses Renal Cell Carcinoma (RCC), Urothelial Cancer, Bladder Cancer, Nephrectomy, and Lymphadenectomy.

 
 
 
 
Learn about our expert tiers
Learn More
Elite in Urothelial Cancer
Elite in Urothelial Cancer
Referral may be required

UT MD Anderson Cancer Center

210 Ashville Ave # 408, 
Cary, NC 
713-792-6161
Languages Spoken:
English
See accepted insurances

Ashish Kamat is a Urologist practicing medicine in Cary, North Carolina. Dr. Kamat is rated as an Elite provider by MediFind in the treatment of Urothelial Cancer. He is also highly rated in 15 other conditions, according to our data. His clinical expertise encompasses Bladder Cancer, Non-Muscle Invasive Bladder Cancer, Muscle Invasive Bladder Cancer, Cystectomy, and Lymphadenectomy.

View All Doctors
What are the latest Urothelial Cancer Clinical Trials?
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)
A Phase 2A/B, Multi-center, Open-Label Study Evaluating the Efficacy and Safety of Dabogratinib (TYRA-300) in Participants With Low Grade Upper Tract Urothelial Carcinoma (SURF303)
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Drug
Study Phase: Phase 2

Summary: A Phase 2A/B study of Dabogratinib (TYRA-300) in Low Grade Upper Tract Urothelial Carcinoma

Match to trials
Find the right clinical trials for you in under a minute
Get started
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
A Phase II Study of Ipilimumab, Cabozantinib, and Nivolumab in Rare Genitourinary Cancers (ICONIC)
Who is this study for: Adult patients with Genitourinary Tumors
Enrollment Status: Recruiting
Publish Date: September 08, 2026
Intervention Type: Procedure, Biological, Drug
Study Drugs: Cabozantinib, Ipilimumab, Nivolumab
Study Phase: Phase 2

Summary: This phase II trial studies how well cabozantinib works in combination with nivolumab and ipilimumab in treating patients with rare genitourinary (GU) tumors that has spread from where it first started (primary site) to other places in the body. Cabozantinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Immunotherapy with monoclonal antibodies, such as ...

View All Clinical Trials